HOME >> BIOLOGY >> NEWS
New Anti-HIV Therapies Needed To Eradicate HIV

Currently approved anti-HIV drug combinations are remarkably effective at reducing the amount of HIV in many patients to undetectable blood levels. For most, the clinical benefits add up to a healthier, longer life. Yet two studies in this week's New England Journal of Medicine demonstrate that, as good as these drugs are at suppressing HIV, other approaches likely will be needed to knock out the last vestiges of the virus.

"These findings are not unexpected," comments Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), which provided major support for both studies. "The data add to other recent findings indicating that it may be impossible to eradicate HIV from the body with currently approved antiretroviral therapy. What all these studies underscore is the pressing need to develop more effective, less toxic medications that can be used over the long term to suppress HIV, as well as novel strategies to then purge residual virus from the body and boost the immune system. In this regard, many important leads are being pursued by investigators in government, academia and industry."

The era of highly active antiretroviral therapy, or HAART, began about three years ago when the first protease inhibitors were incorporated into multi-drug HIV treatment regimens that included older anti-HIV drugs such as AZT. Hopes that the drugs could "cure" AIDS were raised when some patients experienced dramatic drops in the level of HIV in their plasma. More sophisticated studies, however, subsequently turned up evidence that some virus survived the therapy by hiding in certain cells and tissues.

The NEJM studies were conducted by separate groups of investigators from the Aaron Diamond AIDS Research Center in New York, led by Linqui Zhang, Ph.D., and David Ho, M.D., and from Northwestern University Medical School in Chicago, led by Manohar Furtado, Ph.D., and Steven Wolinsky, M.D. Both groups focused attentio
'"/>

Contact: Laurie K. Doepel
ldoepel@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-May-1999


Page: 1 2 3

Related biology news :

1. Anti-HIV statisticians win $1.125 million NIH Merit Award
2. Anti-HIV drugs save vision, improve outlook for AIDS patients
3. Image-guided Therapies
4. UCSF Team Identifies Two Key Molecules In Asthma; Important Finding For New Therapies That Treat Disease At Cell Level
5. Genetically Engineered Mice Show Characteristic Signs Of Alzheimers, Could Be Ideal Tool For Testing New Therapies
6. Penn Researchers Prove "Short-Cut" Function Of Myelin Sheath Channel: BetterUnderstanding Of Myelin Should Lead To Therapies For Neuropathies
7. New Insights On Sequence of Cell Death After Brain Injury: Understanding Cellular Events After Brain Trauma Could Lead To Better Therapies
8. Harvard Medical School Researchers Identify Four Human Genes Essential To Cell Division; Discovery Yields New Target For Cancer Therapies
9. Novel AIDS-Directed Technology: Approach Permits Optimization Of Existing Drug Therapies And Targeted, Patient-Specific Treatment
10. Plant-Based Therapies Examined For Colon Cancer Prevention
11. Discovery Could Help Understand Breast-Cancer Therapies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) ... severe COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 ...
(Date:8/12/2020)... ... 2020 , ... Both Roche, based in Basel, Switzerland, and ... with Housey Pharma’s HMI subsidiary to gain access to its core-enabling technology for ... Development spending in excess of US $10 billion. , Scientists at Housey Pharma ...
(Date:8/5/2020)... , ... August 05, 2020 , ... Regenative Labs has ... new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be ... a syringe. The company’s solutions are the first Wharton’s jelly allograft product to be ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... COLLEGE STATION, Texas (PRWEB) , ... July 29, ... ... pre-qualified cleanroom solutions today announced the launch of its new tagline, “BUILDING FOR ... within the biopharmaceutical industry and around the globe, requiring fast track capacity to ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, Inc. ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and ... a strategic partnership whereby Catalent will provide support for the development, manufacturing, and ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... the life sciences industry, today announced the release of its signature product ... Medical Science Liaisons (MSLs) and other field medical professionals. , Beacon ...
(Date:7/18/2020)... ... , ... “We are thrilled to deliver this new technology to the industry” ... kind on the market and we were pleased that the IFT jury recognized that.” ... ingredients, creating a natural way to extend the shelf life and improve the safety ...
Breaking Biology Technology:
Cached News: